Role of p53 suppression in the pathogenesis of hepatocellular carcinoma

Table 1 List of clinical trials undergoing for hepatocellular carcinoma targeting p53

NCT No.	Title	Drug	Present status	Population	Phase	Date	Location
NCT02418988	Trans-catheter Chemo-embolization combined with rAd-p53 gene injection in treatment of advanced HCC	TACE plus rAd-p53 artery injection	Unknown status	Estimated enrolment: 120 participants. Age: 18 years to 80 years (Adult, older adult)	Advanced adult HCC: Phase 2	Study start study: July 2014. Primary completion study: May 2017. Study completion date: December 2017	China, Shanxi
NCT02509169	Trans-catheter Chemo-embolization combined with p53 gene therapy for treatment of advanced HCC	TAE plus p53 gene	Unknown status	Estimated enrolment: 60 participants. Age: 18 years to 85 years	Advanced HCC: Phase 2	Study start study: October 2014. Primary completion study: December 2016. Study completion date: December 2016	China, Liaoning
NCT02561546	p53 gene therapy in Treatment of diabetes concurrent with HCC	p53 gene therapy	Unknown status	Estimated enrolment: 40 participants. Age: 18 years to 85 years	HCC: Phase 2	Study start study: December 2015. Primary completion study: October 2017. Study completion date: December 2017	China, Liaoning
NCT00003147	Gene therapy in treating patients with cancer of the liver	Ad5CMV-p53 gene	Terminated	Actual enrolment: 30 participants. Age: 18 years and older (Adult, older adult)	Liver cancer: Phase 2	First posted: August 24, 2004. Last Update posted: February 5, 2013	United States, New York. United States, Pennsylvania
NCT02432963	Vaccine therapy and pembrolizumab in treating patients with solid tumours that have failed prior therapy	Modified Vaccinia Virus Ankara Vaccine Expressing p53	Active and recruiting	Actual enrolment: 11 participants. Age: 18 years and older (Adult, older adult)	HCC: Phase 1	First posted: May 4, 2015. Last Update posted: March 21, 2023	United States, California
NCT03544723	Safety and efficacy of p53 gene therapy combined with Immune checkpoint inhibitors in solid tumours	Ad-p53	Unknown status	Estimated enrolment: 40 participants. Age: 18 years and older (Adult, older adult)	Solid tumour: Phase 2	Study start study: October 1, 2018. Primary completion study: June 30, 2022. Study completion date: December 31, 2022	United States, Illinois